| Identification | Back Directory | [Name]
(1R,2S)-VU0155041 | [CAS]
1263273-14-8 | [Synonyms]
2S)-VU0155041
(1R,2S)-VU0155041
(1R,2S)VU0155041,(1R,2S) VU0155041,(1R,2S)-VU-0155041
Cyclohexanecarboxylic acid, 2-[[(3,5-dichlorophenyl)amino]carbonyl]-, (1R,2S)- | [Molecular Formula]
C14H15Cl2NO3 | [MDL Number]
MFCD26142602 | [MOL File]
1263273-14-8.mol | [Molecular Weight]
316.18 |
| Chemical Properties | Back Directory | [Boiling point ]
540.2±50.0 °C(Predicted) | [density ]
1.429±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 59 mg/mL (186.60 mM) | [form ]
Solid | [pka]
4.48±0.44(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM. | [in vivo]
VU0155041 is soluble in an aqueous vehicle and intracerebroventricular administration of 31 to 316 nM of VU0155041 dose-dependently decreases haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041, at doses of 31 and 92 nmol, is also able to significantly decrease the cataleptic effects of haloperidol, and the effects of the compound are still present 30 min after infusion. Icv infusion of a 316 nmol dose of VU0155041 also results in a significant reversal of akinesia[1]. | [IC 50]
mGluR4 | [storage]
Store at -20°C | [References]
[1] Niswender CM, et al. Discovery, characterization, and antiparkinsonian effect of novel positiveallosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov;74(5):1345-58. DOI:10.1124/mol.108.049551 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|